Improving Hashimoto’s thyroiditis by eradicating Blastocystis hominis: Relation to IL-17
| Autor: | Mona Mohamed Tolba, Hanaa Abdalbasit Abdalsamea, Huda Fahmy Farag, Hanaa Tarek El-Zawawy |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0303 health sciences
Blastocystis biology business.industry Endocrinology Diabetes and Metabolism Interleukin medicine.disease biology.organism_classification Thyroiditis Pathogenesis 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Immunology Medicine Interleukin 17 business 030304 developmental biology |
| Zdroj: | Therapeutic Advances in Endocrinology and Metabolism. 11:204201882090701 |
| ISSN: | 2042-0196 2042-0188 |
| DOI: | 10.1177/2042018820907013 |
| Popis: | Background: Hashimoto’s thyroiditis (HT) is a common autoimmune disorder that causes significant morbidity. Interleukin (IL)-17 was identified as a major contributing factor in the pathogenesis of HT. Blastocystis hominis (BH) is a very common infection and has been shown to be associated with several diseases. Our aim was to determine serum IL-17 level in HT patients with and without BH infection and the effect of eradicating BH in patients with HT. Methods: A prospective cohort study was conducted on 20 HT patients not infected with BH (group I), 20 HT patients infected with BH (group II), and 20 healthy patients (group III). Serum free triiodothyronine (FT3), free thyroxine (FT4), thyroid stimulating hormone (TSH), thyroid peroxidase antibodies (anti-TPO), and IL-17 were performed by ELISA method and were repeated in group II after 6 weeks of eradication of BH. Results: Patients with HT showed a significantly higher serum IL-17 compared with controls. IL-17 was significantly higher in HT patients infected with BH compared with HT patients not BH infected (mean 6.93 ± 2.83 pg/ml versus 3.25 ± 1.55 pg/ml, p = 0.003). After BH eradication TSH, anti-TPO, and IL-17 were significantly decreased (mean 14.76 ± 11.11 µIU/ml versus 9.39 ± 7.11 µIU/ml, p Conclusion: Treatment of BH infection ameliorates HT through reduction in IL-17, anti-TPO, and TSH. Clinical trial registration number: PACTR201909495111649 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|